Mbs Lifescience Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 15.80 Cr
- Revenue Growth -4.45%
- Profit Growth -30.26%
- Ebitda 21.24%
- Net Worth 63.80%
- Total Assets 17.45%
About Mbs Lifescience
Mbs Lifescience Private Limited (MLPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 October 2020 (Four years and three months 9 days old ). Its registered office is in Solan, Himachal Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹15.80 Cr.
Sumit Aggarwal and Akash Gupta serve as directors at the Company.
Company Details
-
Location
Solan, Himachal Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U33119HP2020PTC008181
-
Company No.
008181
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
30 Oct 2020
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Himachal Pradesh
Industry
Who are the key members and board of directors at Mbs Lifescience?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumit Aggarwal
|
Director | 30-Oct-2020 | Current |
|
Akash Gupta
|
Director | 30-Oct-2020 | Current |
Financial Performance of Mbs Lifescience.
Mbs Lifescience Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.45% decrease. The company also saw a substantial fall in profitability, with a 30.26% decrease in profit. The company's net worth Soared by an impressive increase of 63.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mbs Lifescience?
In 2023, Mbs Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹158.00 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 12.50 Cr
- Hdfc Bank Limited : 3.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 May 2023 | Axis Bank Limited | ₹4.00 Cr | Open |
| 06 Feb 2023 | Axis Bank Limited | ₹8.50 Cr | Open |
| 17 Dec 2021 | Hdfc Bank Limited | ₹3.00 Cr | Open |
| 18 Sep 2021 | Hdfc Bank Limited | ₹3.00 M | Open |
How Many Employees Work at Mbs Lifescience?
Unlock and access historical data on people associated with Mbs Lifescience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mbs Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mbs Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
